Cannon L A, John J, LaLonde J
Cannon Cardiac and Vascular Research Center and St. Mary's Hospital, Saginaw, Michigan, USA.
Echocardiography. 2001 Apr;18(3):219-23. doi: 10.1046/j.1540-8175.2001.00219.x.
This article focuses on the use of catheter-delivered ultrasound as a device for treatment of coronary arterial total occlusion (CTO). The standard treatment of CTO is reviewed and serves as the basis for the need for new treatment options, such as catheter-delivered ultrasound (SONICROSS). The results of FDA-approved Phase I and Phase II clinical trials using SONICROSS for refractory CTO are described. The Phase II trials indicate that the SONICROSS-facilitated guidewire passage in 71% of CTOs are otherwise refractory to guidewire passage. However, at present, the SONICROSS catheter system is limited in its ability to be delivered reliably to the CTO because of catheter size and trackability.
本文重点关注经导管超声作为治疗冠状动脉完全闭塞（CTO）的一种设备的应用。回顾了CTO的标准治疗方法，并以此为基础说明需要诸如经导管超声（SONICROSS）等新的治疗选择的必要性。描述了美国食品药品监督管理局（FDA）批准的使用SONICROSS治疗难治性CTO的I期和II期临床试验结果。II期试验表明，在71%的CTO病例中，SONICROSS有助于导丝通过，否则这些病例的导丝通过会很困难。然而，目前由于导管尺寸和可跟踪性，SONICROSS导管系统在可靠送达CTO病变部位的能力方面存在局限。
